{
  "$schema": "folio-library-document/v1",
  "id": "10665-332907",
  "title": "Package of care for children and adolescents with advanced HIV disease: stop AIDS: technical brief",
  "variant": "pdf",
  "pages": 32,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "ABBREVIATIONS",
      "number": null,
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-abbreviations"
    },
    {
      "level": 1,
      "title": "ACKNOWLEDGEMENTS",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-acknowledgements"
    },
    {
      "level": 1,
      "title": "BACKGROUND",
      "number": null,
      "page": 9,
      "pageLabel": "1",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-002-background"
    },
    {
      "level": 2,
      "title": "Current WHO guidelines on managing advanced HIV disease",
      "number": null,
      "page": 10,
      "pageLabel": "2",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-003-current-who-guidelines-on-managing-advanced-hiv"
    },
    {
      "level": 1,
      "title": "SCREEN",
      "number": null,
      "page": 13,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-004-screen"
    },
    {
      "level": 2,
      "title": "Tuberculosis",
      "number": null,
      "page": 13,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-005-tuberculosis"
    },
    {
      "level": 2,
      "title": "Cryptococcal disease",
      "number": null,
      "page": 15,
      "pageLabel": "7",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-006-cryptococcal-disease"
    },
    {
      "level": 1,
      "title": "TREAT",
      "number": null,
      "page": 16,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-007-treat"
    },
    {
      "level": 2,
      "title": "Tuberculosis",
      "number": null,
      "page": 16,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-008-tuberculosis"
    },
    {
      "level": 2,
      "title": "Severe pneumonia",
      "number": null,
      "page": 16,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-009-severe-pneumonia"
    },
    {
      "level": 2,
      "title": "Severe bacterial infections",
      "number": null,
      "page": 16,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-010-severe-bacterial-infections"
    },
    {
      "level": 2,
      "title": "Cryptococcal meningitis",
      "number": null,
      "page": 17,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-011-cryptococcal-meningitis"
    },
    {
      "level": 2,
      "title": "Malnutrition",
      "number": null,
      "page": 17,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-012-malnutrition"
    },
    {
      "level": 1,
      "title": "OPTIMIZE",
      "number": null,
      "page": 18,
      "pageLabel": "10",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-013-optimize"
    },
    {
      "level": 2,
      "title": "Counselling and support",
      "number": null,
      "page": 18,
      "pageLabel": "10",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-014-counselling-and-support"
    },
    {
      "level": 1,
      "title": "PREVENT",
      "number": null,
      "page": 19,
      "pageLabel": "11",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-015-prevent"
    },
    {
      "level": 2,
      "title": "Preventing TB, Pneumocystis pneumonia, bacterial infections and cryptococcal disease",
      "number": null,
      "page": 19,
      "pageLabel": "11",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-016-preventing-tb-pneumocystis-pneumonia-bacterial-i"
    },
    {
      "level": 2,
      "title": "PCP and other infections",
      "number": null,
      "page": 20,
      "pageLabel": "12",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-017-pcp-and-other-infections"
    },
    {
      "level": 2,
      "title": "Vaccinations",
      "number": null,
      "page": 21,
      "pageLabel": "13",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-018-vaccinations"
    },
    {
      "level": 1,
      "title": "IMPLEMENTATION CONSIDERATIONS",
      "number": null,
      "page": 25,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-019-implementation-considerations"
    },
    {
      "level": 2,
      "title": "National level",
      "number": null,
      "page": 25,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-020-national-level"
    },
    {
      "level": 2,
      "title": "Facility level",
      "number": null,
      "page": 25,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-021-facility-level"
    },
    {
      "level": 2,
      "title": "Health-care providers",
      "number": null,
      "page": 26,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-022-health-care-providers"
    },
    {
      "level": 2,
      "title": "Laboratory",
      "number": null,
      "page": 26,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-023-laboratory"
    },
    {
      "level": 2,
      "title": "Monitoring and evaluation",
      "number": null,
      "page": 26,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-024-monitoring-and-evaluation"
    },
    {
      "level": 1,
      "title": "RESEARCH GAPS",
      "number": null,
      "page": 28,
      "pageLabel": "20",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-025-research-gaps"
    },
    {
      "level": 2,
      "title": "Clinical research",
      "number": null,
      "page": 28,
      "pageLabel": "20",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-026-clinical-research"
    },
    {
      "level": 2,
      "title": "Operational research",
      "number": null,
      "page": 28,
      "pageLabel": "20",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-027-operational-research"
    },
    {
      "level": 1,
      "title": "REFERENCES",
      "number": null,
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-028-references"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 6,
      "labelStart": "a",
      "labelEnd": "iv",
      "words": 2470,
      "summary": {
        "text": "The front matter of the July 2020 WHO technical brief setting out a Stop AIDS care package for children and adolescents whose HIV disease is advanced, with ISBNs, copyright licence, disclaimers and a table of contents covering screening, treatment, optimization, prevention, implementation and research gaps.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "stop aids",
          "heading": false
        },
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "technical brief",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "bacterial infections",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        }
      ],
      "extract": "TECHNICAL BRIEF — JULY 2020 PACKAGE OF CARE FOR CHILDREN AND ADOLESCENTS WITH ADVANCED HIV DISEASE: STOP AIDS TECHNICAL BRIEF — JULY 2020 PACKAGE OF CARE FOR CHILDREN AND ADOLESCENTS WITH ADVANCED HIV DISEASE: STOP AIDS Package of care for children and adolescents with advanced HIV disease: stop AIDS. Technical brief ISBN 978-92-4-000804-5 (electronic version) ISBN 978-92-4-000805-2 (print version) © World Health",
      "extractCut": true,
      "blocks": [
        "library/10665-332907/blocks/prose-sec-front-matter",
        "library/10665-332907/blocks/figure-img-p001-1"
      ]
    },
    {
      "id": "sec-000-abbreviations",
      "number": null,
      "title": "ABBREVIATIONS",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 7,
      "labelStart": "iv",
      "labelEnd": "v",
      "words": 27,
      "summary": {
        "text": "A list of abbreviations used in the brief, mainly antiretroviral and tuberculosis drug names and tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lpv",
          "heading": false
        },
        {
          "term": "efv",
          "heading": false
        },
        {
          "term": "bacille",
          "heading": false
        }
      ],
      "extract": "BCG Bacille Calmette-Guérin DTG dolutegravir EFV efavirenz E ethambutol H isoniazid HPV human papillomavirus LF-LAM lateral flow urine lipoarabinomannan LPV/r lopinavir/ritonavir R rifampicin TB tuberculosis Z pyrazinamide",
      "extractCut": false
    },
    {
      "id": "sec-001-acknowledgements",
      "number": null,
      "title": "ACKNOWLEDGEMENTS",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 9,
      "labelStart": "v",
      "labelEnd": "1",
      "words": 190,
      "summary": {
        "text": "Acknowledges the WHO programme staff, partner organizations and experts who contributed to the technical brief on advanced HIV disease in children and adolescents. It names contributors from bodies such as ICAP, the Elizabeth Glaser Pediatric AIDS Foundation, the Clinton Health Access Initiative and Médecins Sans Frontières.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "university",
          "heading": false
        },
        {
          "term": "stis programme",
          "heading": false
        },
        {
          "term": "martina",
          "heading": false
        },
        {
          "term": "united states",
          "heading": false
        },
        {
          "term": "college",
          "heading": false
        },
        {
          "term": "brief",
          "heading": false
        },
        {
          "term": "hepatitis",
          "heading": false
        },
        {
          "term": "foundation",
          "heading": false
        }
      ],
      "extract": "The Global HIV, Hepatitis and STIs Programme of WHO gratefully acknowledges the contributions of many individuals and organizations to developing this policy brief. Lisa Frigati led the development of the brief with the contribution of several partners and experts: Nandita Sugandhi (ICAP, Columbia University); Eleanor Magongo (Ministry of Health, Uganda), Yusuf Bhamu, Martina Casenghi, Jennifer Cohn, Judith Kose,",
      "extractCut": true
    },
    {
      "id": "sec-002-background",
      "number": null,
      "title": "BACKGROUND",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 10,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 153,
      "summary": {
        "text": "Sets out the main causes of illness and death in children with HIV in low- and middle-income countries, such as pneumonia, TB and malnutrition, and explains that the brief builds on WHO's 2017 advanced HIV disease guidelines. It notes that many interventions also apply to children without advanced disease.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "adolescents living",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "hiv disease",
          "heading": false
        },
        {
          "term": "pneumonia",
          "heading": false
        }
      ],
      "extract": "The major causes of morbidity and mortality among children living with HIV in low- and middle-income countries are pneumonia (including Pneumocystis pneumonia), tuberculosis (TB), bloodstream infections, diarrhoeal disease and severe acute malnutrition (1,2). In addition, for adolescents living with HIV, adult-type opportunistic infections also occur, including cryptococcal meningitis (3,4). WHO published guidelines",
      "extractCut": true
    },
    {
      "id": "sec-003-current-who-guidelines-on-managing-advanced-hiv",
      "number": null,
      "title": "Current WHO guidelines on managing advanced HIV disease",
      "level": 2,
      "pageStart": 10,
      "pageEnd": 13,
      "labelStart": "2",
      "labelEnd": "5",
      "words": 939,
      "summary": {
        "text": "Summarizes WHO's 2017 guidance on advanced HIV disease, defining it for children and noting that all children under five are considered to have advanced disease, with exceptions for those stable on treatment. It explains that the evidence base comes mainly from adult trials such as REMSTART and REALITY. It then outlines the screening, prophylaxis and treatment recommendations relevant to children and adolescents, including that cryptococcal screening is not advised under age 10.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "advanced disease",
          "heading": true
        },
        {
          "term": "advanced hiv",
          "heading": true
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "blood cryptococcal",
          "heading": false
        },
        {
          "term": "pre-emptive therapy",
          "heading": false
        },
        {
          "term": "fluconazole pre-emptive",
          "heading": false
        },
        {
          "term": "children younger",
          "heading": false
        }
      ],
      "extract": "advanced HIV disease In 2017, WHO published guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy (5). Advanced HIV disease is defined as WHO stage 3 or 4 or a CD4 cell count <200 cells/mm3 for children five years or older. All children younger than five years are considered to have advanced disease (5). This is based on the rationale that most children younger than five years",
      "extractCut": true
    },
    {
      "id": "sec-004-screen",
      "number": null,
      "title": "SCREEN",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-005-tuberculosis",
      "number": null,
      "title": "Tuberculosis",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 15,
      "labelStart": "5",
      "labelEnd": "7",
      "words": 617,
      "summary": {
        "text": "Describes the high incidence of TB in children with HIV and the symptoms used to screen for it, noting the overlap with other HIV-related signs. It covers the limits of urine LF-LAM testing in children, the 2019 LAM recommendations and the advantages of rapid molecular tests such as Xpert MTB/RIF, while stressing the continuing role of clinical diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cell count",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "adolescents living",
          "heading": false
        },
        {
          "term": "lf-lam guidelines",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        }
      ],
      "extract": "The incidence of TB in a cohort of children living with HIV in Uganda and Zimbabwe ranged from 1.2 to 8.8 per 100 child-years, and an estimated 15% of children starting antiretroviral therapy in sub-Saharan Africa develop TB (14,15). Although antiretroviral therapy reduces children’s risk of TB infection, its full protective potential is only evident 1–2 years after starting antiretroviral therapy (8). TB is",
      "extractCut": true
    },
    {
      "id": "sec-006-cryptococcal-disease",
      "number": null,
      "title": "Cryptococcal disease",
      "level": 2,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 148,
      "summary": {
        "text": "Explains that cryptococcal disease is rare in young children with HIV, so antigen screening is recommended only for adolescents, and lists useful WHO resources on TB diagnostics and HIV guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal disease",
          "heading": true
        },
        {
          "term": "children younger",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "five years",
          "heading": false
        },
        {
          "term": "emptive",
          "heading": false
        }
      ],
      "extract": "In contrast to adults, cryptococcal disease is rare, especially among children younger than five years of age. In a laboratory-based survey performed in South Africa, the incidence of cryptococcal disease was estimated to be 47 per 100 000 children living with HIV in 2007 (26), and within two trial cohorts of children living with HIV, no cases of cryptococcal disease were reported for children younger than five",
      "extractCut": true
    },
    {
      "id": "sec-007-treat",
      "number": null,
      "title": "TREAT",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-008-tuberculosis",
      "number": null,
      "title": "Tuberculosis",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 140,
      "summary": {
        "text": "Describes child-friendly fixed-dose TB treatment formulations and how to manage drug interactions between rifampicin and lopinavir/ritonavir or dolutegravir in children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drug interactions",
          "heading": false
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "lpv",
          "heading": false
        },
        {
          "term": "dispersible",
          "heading": false
        },
        {
          "term": "dtg",
          "heading": false
        }
      ],
      "extract": "Treatment for drug-sensitive TB among children comprises a four-drug regimen that includes rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E). A child-friendly, fixed- dose combination, dispersible tablet of RHZ is available and can be taken with a 100-mg child friendly formulation of E (intensive-phase treatment). In addition, there is a child-friendly, dispersible fixed-dose combination of RH for",
      "extractCut": true
    },
    {
      "id": "sec-009-severe-pneumonia",
      "number": null,
      "title": "Severe pneumonia",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 234,
      "summary": {
        "text": "Covers the bacterial causes of severe pneumonia in children with HIV, classification by IMCI algorithms and high-dose co-trimoxazole for suspected Pneumocystis pneumonia in young infants. It notes that for children aged one to five, standard WHO antibiotics are preferred over co-trimoxazole.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "severe pneumonia",
          "heading": true
        },
        {
          "term": "pneumocystis pneumonia",
          "heading": false
        },
        {
          "term": "pneumonia among",
          "heading": false
        },
        {
          "term": "antibiotics recommended",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "co-trimoxazole",
          "heading": false
        },
        {
          "term": "empirical",
          "heading": false
        }
      ],
      "extract": "In studies of severe pneumonia among children living with HIV, the most common bacterial pathogens isolated were predominantly Streptococcus pneumoniae and Staphylococcus aureus, pathogens that may be effectively covered by commonly available and recommended antibacterial medications (29). The severity of illness and need for hospitalization should be classified according to the WHO integrated management of",
      "extractCut": true
    },
    {
      "id": "sec-010-severe-bacterial-infections",
      "number": null,
      "title": "Severe bacterial infections",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 111,
      "summary": {
        "text": "Describes high rates of bacteraemia in children starting antiretroviral therapy and the pathogens involved, advising treatment according to WHO guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bacteraemia",
          "heading": false
        },
        {
          "term": "infections",
          "heading": true
        },
        {
          "term": "gram-negative",
          "heading": false
        },
        {
          "term": "care-associated",
          "heading": false
        }
      ],
      "extract": "High rates of bacteraemia have been described in children starting antiretroviral therapy, especially within the first three months of treatment (35,36). A recent study of 82 children with malnutrition admitted to a tertiary hospital in Durban, South Africa showed that 6% of admission blood cultures were positive. Community-associated infections were primarily Streptococcus or Staphylococcus. Health care-associated",
      "extractCut": true
    },
    {
      "id": "sec-011-cryptococcal-meningitis",
      "number": null,
      "title": "Cryptococcal meningitis",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 54,
      "summary": {
        "text": "Gives the preferred one-week amphotericin B and flucytosine induction regimen for cryptococcal meningitis in children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal",
          "heading": true
        },
        {
          "term": "meningitis",
          "heading": true
        },
        {
          "term": "day",
          "heading": false
        }
      ],
      "extract": "Guidelines for cryptococcal meningitis treatment have been revised, and a short-course (one- week) induction regimen with amphotericin B deoxycholate (1.0 mg/kg per day) and flucytosine (100 mg/kg per day, divided into four doses per day) is the preferred option for children living with HIV. Further recommendations are available in the 2018 WHO guidelines (13).",
      "extractCut": false
    },
    {
      "id": "sec-012-malnutrition",
      "number": null,
      "title": "Malnutrition",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 188,
      "summary": {
        "text": "Notes that severe acute malnutrition is common and deadly at HIV diagnosis and that malnutrition treatment should be part of children's HIV programmes. It then lists useful resources on child TB formulations, pneumonia management and malnutrition.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "malnutrition",
          "heading": true
        },
        {
          "term": "acute malnutrition",
          "heading": false
        },
        {
          "term": "severe acute",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "geneva",
          "heading": false
        }
      ],
      "extract": "Severe acute malnutrition is common at HIV diagnosis and carries a high risk of mortality. The availability of malnutrition treatment programmes and commodities, including ready- to-use therapeutic food where appropriate, can be considered as essential components of HIV treatment programmes for children. Useful resources WHO, UNICEF. Statement on the use of child-friendly fixed-dose combinations for the treatment of",
      "extractCut": true
    },
    {
      "id": "sec-013-optimize",
      "number": null,
      "title": "OPTIMIZE",
      "level": 1,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 251,
      "summary": {
        "text": "Reviews trials from South Africa and Kenya on the timing of antiretroviral therapy in children with severe acute malnutrition or hospitalization. It also stresses the risk of loss to follow-up and the need to link children to ongoing HIV care at discharge.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "acute malnutrition",
          "heading": false
        },
        {
          "term": "initiating antiretroviral",
          "heading": false
        },
        {
          "term": "therapy initiation",
          "heading": false
        },
        {
          "term": "severe acute",
          "heading": false
        },
        {
          "term": "median age",
          "heading": false
        },
        {
          "term": "randomized trial",
          "heading": false
        },
        {
          "term": "age months",
          "heading": false
        }
      ],
      "extract": "In a randomized trial from South Africa, young children living with HIV (median age 23 months) with severe acute malnutrition were randomized to receive antiretroviral therapy within 14 days of admission or for antiretroviral therapy to be delayed until nutritional recovery (and after two weeks; median time 23 days) (39). The results suggested that a short delay in antiretroviral therapy initiation during early",
      "extractCut": true
    },
    {
      "id": "sec-014-counselling-and-support",
      "number": null,
      "title": "Counselling and support",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 94,
      "summary": {
        "text": "Calls for more counselling and adolescent-friendly adherence support with earlier treatment initiation, and lists counselling resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "counselling",
          "heading": true
        },
        {
          "term": "icap",
          "heading": false
        },
        {
          "term": "columbia",
          "heading": false
        },
        {
          "term": "mailman",
          "heading": false
        }
      ],
      "extract": "Additional counselling and support are needed with earlier antiretroviral therapy initiation. Counselling tools have been updated to reflect newer optimal regimens and formulations. Adolescents generally face challenges in adhering to medication, and adolescent- friendly services, including enhanced adherence counselling, adolescent peer counsellors and support groups, may be especially valuable. Useful resources",
      "extractCut": true
    },
    {
      "id": "sec-015-prevent",
      "number": null,
      "title": "PREVENT",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-016-preventing-tb-pneumocystis-pneumonia-bacterial-i",
      "number": null,
      "title": "Preventing TB, Pneumocystis pneumonia, bacterial infections and cryptococcal disease",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 508,
      "summary": {
        "text": "Covers TB preventive treatment for children with HIV, including the restricted use in infants without a TB contact and the preferred six-month isoniazid regimen with pyridoxine. It describes shorter rifampicin- or rifapentine-based options, their interactions with antiretroviral drugs in a summary table, and related resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "studied among",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "drug interaction",
          "heading": false
        },
        {
          "term": "rifapentine",
          "heading": false
        },
        {
          "term": "major ddi",
          "heading": false
        },
        {
          "term": "ddi expected",
          "heading": false
        }
      ],
      "extract": "bacterial infections and cryptococcal disease Tuberculosis TB preventive treatment has been shown to reduce morbidity and mortality among children living with HIV one year and older even if they do not have a known TB contact (41). Despite this, TB preventive treatment has not yet been fully implemented as part of comprehensive HIV care for children and adolescents (42). TB preventive treatment is currently not",
      "extractCut": true
    },
    {
      "id": "sec-017-pcp-and-other-infections",
      "number": null,
      "title": "PCP and other infections",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "12",
      "labelEnd": "13",
      "words": 589,
      "summary": {
        "text": "Reviews evidence on co-trimoxazole prophylaxis to prevent Pneumocystis pneumonia and other infections in children with HIV and when it may be stopped. It also addresses fluconazole and cryptococcal antigen screening for adolescents, including lumbar puncture for those who test positive.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumocystis pneumonia",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "azithromycin",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "bacterial infections",
          "heading": false
        },
        {
          "term": "count cells",
          "heading": false
        },
        {
          "term": "receiving antiretroviral",
          "heading": false
        }
      ],
      "extract": "Co-trimoxazole Studies done in South Africa and Zambia in the era before antiretroviral therapy showed a high prevalence of Pneumocystis pneumonia, with infants younger than six months being especially vulnerable regardless of CD4 cell count (44,45). Despite improved access to antiretroviral therapy, Pneumocystis pneumonia remains a common cause of hospitalization because of undiagnosed HIV among infants.",
      "extractCut": true
    },
    {
      "id": "sec-018-vaccinations",
      "number": null,
      "title": "Vaccinations",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 25,
      "labelStart": "13",
      "labelEnd": "17",
      "words": 1070,
      "summary": {
        "text": "Sets out vaccination guidance for children with HIV, focusing on BCG, human papillomavirus, measles and pneumococcal vaccines, including timing relative to antiretroviral therapy and immune recovery. It notes differences in BCG practice between countries and gives revaccination and catch-up advice. A case study describes scaling up the advanced HIV disease package for children in Malawi using a hub-and-spoke model and the challenges encountered.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pneumococcal conjugate",
          "heading": false
        },
        {
          "term": "measles vaccine",
          "heading": false
        },
        {
          "term": "bcg vaccination",
          "heading": false
        },
        {
          "term": "catch-up vaccination",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "position papers",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        },
        {
          "term": "children younger",
          "heading": false
        }
      ],
      "extract": "The WHO 2017 advanced HIV disease guidelines (5) highlighted the importance of vaccination in preventing severe disease among people living with HIV. Several other important vaccines were specifically recommended, including meningococcal, polio, rotavirus and yellow fever; however, this publication focuses on immunizations for the vaccine-preventable infections that are most significant to children living with HIV:",
      "extractCut": true
    },
    {
      "id": "sec-019-implementation-considerations",
      "number": null,
      "title": "IMPLEMENTATION CONSIDERATIONS",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-020-national-level",
      "number": null,
      "title": "National level",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 131,
      "summary": {
        "text": "Lists national-level implementation steps, such as adopting the guidelines, aligning HIV, TB and child health guidance, procuring child formulations and enabling catch-up vaccination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "guidelines relating",
          "heading": false
        },
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "hiv disease",
          "heading": false
        },
        {
          "term": "commodities",
          "heading": false
        }
      ],
      "extract": "■The recommendations in the 2017 guidelines on advanced HIV disease (5) (and other related updated WHO guidelines) need to be adopted in national policy and guidelines. ■It is important to try to align recommendations across multiple guidelines relating not only to HIV (for example, TB and HIV guidelines relating to TB preventive treatment) but also to routine child health and development interventions (vitamin A,",
      "extractCut": true
    },
    {
      "id": "sec-021-facility-level",
      "number": null,
      "title": "Facility level",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 224,
      "summary": {
        "text": "Lists facility-level considerations for the paediatric advanced HIV disease package, including hub-and-spoke delivery, task shifting, child-friendly settings and equipment. It also stresses functioning referral systems, for example for safe administration of amphotericin B.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "disease package",
          "heading": false
        },
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "regimen based",
          "heading": false
        },
        {
          "term": "mix",
          "heading": false
        },
        {
          "term": "enhanced",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "child",
          "heading": false
        },
        {
          "term": "referral",
          "heading": false
        }
      ],
      "extract": "■Currently, the advanced HIV disease package is being implemented as a hub-and-spoke model. Further guidance on this is available in the global advanced HIV disease toolkit (http://www. differentiatedcare.org/Resources/Resource-Library/Global-Advanced-HIV-DiseaseToolkit). ■In the context of ongoing and enhanced efforts to ensure task shifting for services for children, all cadres of health-care workers need training",
      "extractCut": true
    },
    {
      "id": "sec-022-health-care-providers",
      "number": null,
      "title": "Health-care providers",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 125,
      "summary": {
        "text": "Lists actions for health-care providers, such as training on child health issues and paediatric TB screening, and stresses that clinical diagnosis and treatment of TB should continue when tests are unavailable or negative.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "disease package",
          "heading": false
        },
        {
          "term": "health-care",
          "heading": true
        },
        {
          "term": "child-specific",
          "heading": false
        }
      ],
      "extract": "■Health-care providers should be sensitized on child-specific issues such as growth monitoring and other routine child health interventions. ■Training and capacity building for staff should be implemented in sites where these recommendations are to be implemented. ■Ensure that the advanced HIV disease package is included in any curriculum of training on HIV related to children or adolescents. ■Uptake of TB screening",
      "extractCut": true
    },
    {
      "id": "sec-023-laboratory",
      "number": null,
      "title": "Laboratory",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 62,
      "summary": {
        "text": "Calls for laboratory procedures for collecting specimens from young children and for antibiotic resistance surveillance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "washings",
          "heading": false
        },
        {
          "term": "bags",
          "heading": false
        },
        {
          "term": "transporting",
          "heading": false
        }
      ],
      "extract": "■Ensure that protocols and standard operating procedures are in place for obtaining and transporting specimens from young children. Training and expertise in paediatric phlebotomy and ordering urine bags, gastric washings, sputum induction and stool collection and processing need to be considered. ■Explore the capacity for antibiotic resistance surveillance to ensure that the optimal first-line treatment for severe",
      "extractCut": true
    },
    {
      "id": "sec-024-monitoring-and-evaluation",
      "number": null,
      "title": "Monitoring and evaluation",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 28,
      "labelStart": "18",
      "labelEnd": "20",
      "words": 327,
      "summary": {
        "text": "Calls for monitoring the toxicity of combined preventive therapies and for child-specific monitoring tools. Table 4 lists reference prices and sources for key commodities in the package, such as isoniazid and co-trimoxazole, followed by useful resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "procurement mechanism",
          "heading": false
        },
        {
          "term": "pooled procurement",
          "heading": false
        },
        {
          "term": "fund pooled",
          "heading": false
        },
        {
          "term": "usaid procurement",
          "heading": false
        },
        {
          "term": "global fund",
          "heading": false
        },
        {
          "term": "global price",
          "heading": false
        },
        {
          "term": "rifapentine global",
          "heading": false
        },
        {
          "term": "price discount",
          "heading": false
        }
      ],
      "extract": "■Monitor the potential toxicity of children receiving TB preventive treatment, co-trimoxazole plus antiretroviral therapy (and potentially fluconazole for adolescents). ■Monitoring tools need to be developed for the advanced HIV disease package that are specific to children. Table 4. Cost implications and considerations for commodities Medicines (dosage form and pack size) Reference price excluding transport (USD)",
      "extractCut": true
    },
    {
      "id": "sec-025-research-gaps",
      "number": null,
      "title": "RESEARCH GAPS",
      "level": 1,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-026-clinical-research",
      "number": null,
      "title": "Clinical research",
      "level": 2,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 252,
      "summary": {
        "text": "Lists clinical research gaps in diagnostics, prophylaxis and treatment for children with advanced HIV disease, such as point-of-care pneumonia tests, the role of azithromycin and shorter TB preventive regimens. It also mentions ongoing studies of cryptococcal meningitis treatment that may inform care of older children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "hiv younger",
          "heading": false
        },
        {
          "term": "research gaps",
          "heading": false
        },
        {
          "term": "gaps related",
          "heading": false
        },
        {
          "term": "pneumonia",
          "heading": false
        },
        {
          "term": "cytomegalovirus",
          "heading": false
        }
      ],
      "extract": "Diagnostics ■Research gaps related to diagnostics in children include the need to develop simplified point- of-care diagnostics for pneumonia, specifically Pneumocystis pneumonia and cytomegalovirus disease. ■In addition, the use of rapid molecular tests in stools and other urine LAM assays needs to be further evaluated in children. Prophylaxis ■Whether there is an optimal package of prophylactic interventions for",
      "extractCut": true
    },
    {
      "id": "sec-027-operational-research",
      "number": null,
      "title": "Operational research",
      "level": 2,
      "pageStart": 28,
      "pageEnd": 29,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 52,
      "summary": {
        "text": "Lists ongoing operational research on paediatric TB diagnosis and prevention, such as the CaP TB programme and the TB-Speed study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studied",
          "heading": false
        },
        {
          "term": "tb-speed",
          "heading": false
        },
        {
          "term": "catalyzing",
          "heading": false
        }
      ],
      "extract": "■TB diagnosis and prevention is being studied in several countries in Africa in the Catalyzing Pediatric Tuberculosis Innovations programme (https://unitaid.org/assets/Catalyzing-Pediatric- Tuberculosis-Innovations-CaP-TB.pdf). Enhanced early detection of TB is being studied in the TB-Speed study in seven countries in Africa and Asia (https://www.tb-speed.com). A publication on research priorities for children with",
      "extractCut": true
    },
    {
      "id": "sec-028-references",
      "number": null,
      "title": "REFERENCES",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 32,
      "labelStart": "21",
      "labelEnd": "24",
      "words": 1732,
      "summary": {
        "text": "The reference list of the 2020 technical brief on advanced HIV disease in children, citing studies on hospital admissions, mortality, TB, opportunistic infections and vaccination in children with HIV, followed by WHO HIV department contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "lancet infect",
          "heading": false
        },
        {
          "term": "pediatr infect",
          "heading": false
        },
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "hiv-infected children",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        },
        {
          "term": "lancet hiv",
          "heading": false
        }
      ],
      "extract": "1. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438–44. 2. Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "children living",
      "heading": false
    },
    {
      "term": "among children",
      "heading": false
    },
    {
      "term": "children younger",
      "heading": false
    },
    {
      "term": "children years",
      "heading": false
    },
    {
      "term": "advanced hiv",
      "heading": true
    },
    {
      "term": "antiretroviral therapy",
      "heading": false
    },
    {
      "term": "hiv disease",
      "heading": true
    },
    {
      "term": "children older",
      "heading": false
    },
    {
      "term": "hiv-infected children",
      "heading": false
    },
    {
      "term": "cryptococcal disease",
      "heading": true
    },
    {
      "term": "children starting",
      "heading": false
    },
    {
      "term": "children admitted",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 10,
      "label": "2",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 11,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 16,
      "label": "8",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 17,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 18,
      "label": "10",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "12",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "13",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "17",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "18",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 29,
      "label": "21",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 30,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "24",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "box",
      "number": "1",
      "title": "Screen, Treat, Optimize and Prevent AIDS Screena",
      "page": 11,
      "pageLabel": "3",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "Screening, diagnosis and prevention components of the package of care for children and adoles­",
      "page": 12,
      "pageLabel": "4",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "2",
      "title": "Recommendations from the LF-LAM guidelines from 2019 (11,12)",
      "page": 14,
      "pageLabel": "6",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "TB preventive therapy options and their drug-drug interaction with antiretrovirals used in",
      "page": 19,
      "pageLabel": "11",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "Prophylactic doses of drugs for children based on weight bands: daily administration",
      "page": 21,
      "pageLabel": "13",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "Cost implications and considerations for commodities",
      "page": 27,
      "pageLabel": "19",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p001-1",
      "file": "images/img-p001-1.webp",
      "page": 1,
      "narratives": {
        "en": "Cover photo of a young child in a green vest lying in the arms of an adult wearing a red and yellow patterned sari and bangles, looking toward the camera.",
        "ar": "صورة الغلاف لطفل صغير يرتدي صدرية خضراء مستلقيًا بين ذراعي شخص بالغ يرتدي ساريًا مزخرفًا باللونين الأحمر والأصفر وأساور، وينظر نحو الكاميرا.",
        "zh": "封面照片：一名穿绿色背心的幼儿躺在一位身穿红黄花纹纱丽、戴手镯的成人怀中，望向镜头。",
        "es": "Foto de portada de un niño pequeño con camiseta verde recostado en los brazos de una persona adulta que viste un sari estampado rojo y amarillo y brazaletes, mirando a la cámara.",
        "fr": "Photo de couverture d'un jeune enfant en débardeur vert allongé dans les bras d'un adulte portant un sari à motifs rouges et jaunes et des bracelets, regardant l'objectif.",
        "ru": "Фотография на обложке: маленький ребенок в зеленой майке лежит на руках у взрослого в красно-желтом узорчатом сари и браслетах и смотрит в камеру."
      },
      "state": "draft"
    },
    {
      "id": "img-p009-1",
      "file": "images/img-p009-1.webp",
      "page": 9,
      "narratives": {
        "en": "Photo of three smiling young people sitting close together against a green wall; the woman in the middle wears a T-shirt reading 'Start Free, Stay Free, AIDS Free'.",
        "ar": "صورة لثلاثة شباب مبتسمين يجلسون متقاربين أمام جدار أخضر؛ وترتدي الشابة في الوسط قميصًا مكتوبًا عليه 'Start Free, Stay Free, AIDS Free'.",
        "zh": "照片：三名面带微笑的年轻人靠在绿色墙边坐在一起；中间的女子穿着印有“Start Free, Stay Free, AIDS Free”的T恤。",
        "es": "Foto de tres jóvenes sonrientes sentados juntos contra una pared verde; la mujer del centro lleva una camiseta con el texto «Start Free, Stay Free, AIDS Free».",
        "fr": "Photo de trois jeunes souriants assis côte à côte contre un mur vert ; la femme au centre porte un T-shirt portant l'inscription « Start Free, Stay Free, AIDS Free ».",
        "ru": "Фотография трех улыбающихся молодых людей, сидящих рядом у зеленой стены; на девушке в центре футболка с надписью «Start Free, Stay Free, AIDS Free»."
      },
      "state": "draft"
    },
    {
      "id": "img-p013-1",
      "file": "images/img-p013-1.webp",
      "page": 13,
      "narratives": {
        "en": "Photo of a young girl in a pink dress standing on a concrete floor beside a half-open metal door, with adults standing nearby in the light from outside.",
        "ar": "صورة لطفلة صغيرة ترتدي فستانًا ورديًا تقف على أرضية إسمنتية بجانب باب معدني نصف مفتوح، وبالقرب منها بالغون يقفون في الضوء القادم من الخارج.",
        "zh": "照片：一名穿粉色连衣裙的小女孩站在水泥地上，旁边是一扇半开的金属门，附近有几名成人站在门外透进的光线中。",
        "es": "Foto de una niña pequeña con vestido rosa de pie sobre un suelo de cemento junto a una puerta metálica entreabierta, con personas adultas de pie cerca, a la luz que entra del exterior.",
        "fr": "Photo d'une petite fille en robe rose debout sur un sol en béton à côté d'une porte métallique entrouverte, avec des adultes debout à proximité dans la lumière venant de l'extérieur.",
        "ru": "Фотография маленькой девочки в розовом платье, стоящей на бетонном полу у приоткрытой металлической двери; рядом в свете снаружи стоят взрослые."
      },
      "state": "draft"
    },
    {
      "id": "img-p022-1",
      "file": "images/img-p022-1.webp",
      "page": 22,
      "narratives": {
        "en": "Photo of two health workers in a clinic office sorting supplies on a table, including medicine bottles and a 'Flip Chart'; the walls are covered with notices and posters and the shelves with files.",
        "ar": "صورة لعاملَين صحيين في مكتب عيادة يفرزان مستلزمات على طاولة، منها زجاجات أدوية و'Flip Chart'؛ والجدران مغطاة بالإعلانات والملصقات والرفوف بالملفات.",
        "zh": "照片：两名卫生工作者在诊所办公室的桌上整理物品，包括药瓶和一本“Flip Chart”；墙上贴满通知和海报，书架上放着文件。",
        "es": "Foto de dos trabajadores de la salud en una oficina de un consultorio clasificando suministros sobre una mesa, entre ellos frascos de medicamentos y un «Flip Chart»; las paredes están cubiertas de avisos y carteles y los estantes de archivos.",
        "fr": "Photo de deux agents de santé dans un bureau de dispensaire triant des fournitures sur une table, dont des flacons de médicaments et un « Flip Chart » ; les murs sont couverts d'avis et d'affiches et les étagères de dossiers.",
        "ru": "Фотография двух медработников в кабинете клиники, сортирующих на столе материалы, в том числе флаконы с лекарствами и «Flip Chart»; стены покрыты объявлениями и плакатами, полки — папками."
      },
      "state": "draft"
    },
    {
      "id": "img-p024-1",
      "file": "images/img-p024-1.webp",
      "page": 24,
      "narratives": {
        "en": "Photo of a health worker leaning over a desk and writing in a large paper register next to a small card, with a child seated beside the desk and a tablet on the table.",
        "ar": "صورة لعامل صحي ينحني على مكتب ويكتب في سجل ورقي كبير بجانب بطاقة صغيرة، وبجانب المكتب طفل جالس وعلى الطاولة جهاز لوحي.",
        "zh": "照片：一名卫生工作者俯身在桌前，在一本大纸质登记册上书写，旁边有一张小卡片；桌旁坐着一名儿童，桌上放着平板电脑。",
        "es": "Foto de un trabajador de la salud inclinado sobre un escritorio escribiendo en un gran registro de papel junto a una pequeña tarjeta, con un niño sentado al lado y una tableta sobre la mesa.",
        "fr": "Photo d'un agent de santé penché sur un bureau, écrivant dans un grand registre papier à côté d'une petite carte, avec un enfant assis à côté et une tablette sur la table.",
        "ru": "Фотография медработника, склонившегося над столом и делающего записи в большом бумажном журнале рядом с небольшой карточкой; у стола сидит ребенок, на столе — планшет."
      },
      "state": "draft"
    },
    {
      "id": "img-p032-1",
      "file": "images/img-p032-1.webp",
      "page": 32,
      "narratives": {
        "en": "Back-cover photo of a woman in an orange embroidered sari seen from behind in a dark doorway, carrying a sleeping young child on her shoulder, framed by pink walls and a teal metal door.",
        "ar": "صورة الغلاف الخلفي لامرأة ترتدي ساريًا برتقاليًا مطرزًا تظهر من الخلف عند مدخل مظلم، تحمل طفلًا صغيرًا نائمًا على كتفها، يحيط بها جداران ورديان وباب معدني أزرق مخضر.",
        "zh": "封底照片：一名身穿橙色刺绣纱丽的女子背对镜头站在昏暗的门口，肩上背着一名熟睡的幼儿，两侧为粉色墙壁和一扇青绿色金属门。",
        "es": "Foto de contraportada de una mujer con un sari naranja bordado, vista de espaldas en una entrada oscura, que lleva a un niño pequeño dormido sobre el hombro, enmarcada por paredes rosadas y una puerta metálica verde azulada.",
        "fr": "Photo de quatrième de couverture d'une femme en sari orange brodé, vue de dos dans une embrasure sombre, portant un jeune enfant endormi sur l'épaule, encadrée de murs roses et d'une porte métallique bleu-vert.",
        "ru": "Фотография на задней обложке: женщина в оранжевом сари с вышивкой, видимая со спины в темном дверном проеме, несет на плече спящего маленького ребенка; по бокам — розовые стены и сине-зеленая металлическая дверь."
      },
      "state": "draft"
    },
    {
      "id": "img-p032-2",
      "file": "images/img-p032-2.webp",
      "page": 32,
      "narratives": {
        "en": "ISBN barcode with the number 9789240008045.",
        "ar": "رمز شريطي لرقم ISBN هو 9789240008045.",
        "zh": "ISBN条形码，编号9789240008045。",
        "es": "Código de barras ISBN con el número 9789240008045.",
        "fr": "Code-barres ISBN portant le numéro 9789240008045.",
        "ru": "Штрихкод ISBN с номером 9789240008045."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Screening, diagnosis and prevention components of the package of care for children and adolescents with advanced HIV disease",
      "pages": [
        12
      ],
      "columns": [
        {
          "titles": "Intervention"
        },
        {
          "titles": "Component"
        },
        {
          "titles": "<5 years"
        },
        {
          "titles": "5–9 years"
        },
        {
          "titles": "10–19 years"
        }
      ],
      "rows": [
        [
          "Screening and diagnosis",
          "Screen for TB using clinical algorithm followed by X-ray when indicated and if available\nXpert® MTB/RIF or Xpert® Ultra assay as the first test\n(Induced or expectorated) sputum, gastric aspirate, stool or nasopharyngeal aspirate or other extrapulmonary specimens (induced or expectorated)",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "",
          "LF-LAM assayᵃ",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "",
          "Cryptococcal antigen screening\n(Specimen: Serum, plasma, or whole blood)\nIf blood cryptococcal antigen positive or symptomatic, lumbar puncture",
          "No",
          "No",
          "Yes"
        ],
        [
          "Prevention, prophylaxis and pre-emptive treatment",
          "Pneumococcal conjugate vaccine (catch-up)",
          "Yes",
          "No",
          "No"
        ],
        [
          "",
          "Co-trimoxazoleᵇ",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "",
          "TB preventive treatment",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "",
          "Fluconazole pre-emptive therapy for cryptococcal antigen–positive without evidence of meningitisᶜ",
          "Not applicable",
          "Not applicable",
          "Yes"
        ]
      ],
      "notes": "ᵃ See Box 2 (11,12).\nᵇ See text for when to discontinue.\nᶜ Screening for cryptococcal antigen followed by pre-emptive antifungal therapy among cryptococcal antigen–positive adolescents to prevent the development of invasive cryptococcal disease is recommended before initiating or reinitiating antiretroviral therapy for adolescents living with HIV who have a CD4 cell count <100 cells/mm³ (strong recommendation; moderate-certainty evidence) and may be considered at a higher CD4 cell count threshold of <200 cells/mm³ (conditional recommendation; moderate certainty evidence). When cryptococcal antigen screening is not available, fluconazole primary prophylaxis should be given to adolescents living with HIV who have a CD4 cell count <100 cells/mm³ (strong recommendation; moderate-certainty evidence) and may be considered at a higher CD4 cell count threshold of <200 cells/mm³ (conditional recommendation; moderate-certainty evidence). Screening and primary prophylaxis are not recommended for children younger than 10 years, given the low incidence of cryptococcal meningitis in this age group (13).",
      "narratives": {
        "en": "The table lists the screening and diagnosis, and prevention, prophylaxis and pre-emptive treatment components of the package of care for children and adolescents with advanced HIV disease, indicating (Yes/No) whether each applies to children aged <5, 5–9 and 10–19 years.",
        "ar": "يسرد الجدول مكونات الفحص والتشخيص، والوقاية والاتقاء والعلاج الاستباقي ضمن حزمة الرعاية للأطفال والمراهقين المصابين بمرض فيروس العوز المناعي البشري المتقدم، مع بيان (نعم/لا) ما إذا كان كل مكون ينطبق على الفئات العمرية أقل من 5 سنوات و5–9 سنوات و10–19 سنة.",
        "zh": "该表列出晚期艾滋病毒病儿童和青少年一揽子护理中的筛查和诊断、预防、预防性用药和先发治疗组成部分，并标明（是/否）每一部分是否适用于<5岁、5–9岁和10–19岁年龄组。",
        "es": "La tabla enumera los componentes de cribado y diagnóstico, y de prevención, profilaxis y tratamiento preventivo del paquete de atención para niños y adolescentes con enfermedad avanzada por el VIH, e indica (Sí/No) si cada uno se aplica a los grupos de <5, 5–9 y 10–19 años.",
        "fr": "Le tableau énumère les composantes de dépistage et diagnostic, et de prévention, prophylaxie et traitement préemptif de l’ensemble de soins destiné aux enfants et adolescents atteints d’une infection à VIH à un stade avancé, en indiquant (Oui/Non) si chacune s’applique aux tranches d’âge <5 ans, 5–9 ans et 10–19 ans.",
        "ru": "В таблице перечислены компоненты скрининга и диагностики, а также профилактики и упреждающего лечения в пакете помощи детям и подросткам с продвинутой стадией ВИЧ-инфекции с указанием (да/нет), применяется ли каждый из них в возрастных группах <5, 5–9 и 10–19 лет."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. TB preventive therapy options and their drug-drug interaction with antiretrovirals used in children and adolescents with HIV",
      "pages": [
        19
      ],
      "columns": [
        {
          "titles": "TB preventive treatment regimen"
        },
        {
          "titles": "LPVr"
        },
        {
          "titles": "EFV"
        },
        {
          "titles": "DTG"
        }
      ],
      "rows": [
        [
          "6H",
          "No",
          "No",
          "No"
        ],
        [
          "3RH",
          "Yes",
          "No",
          "Yes"
        ],
        [
          "3HP",
          "Yes",
          "Being studied but no major DDI expected",
          "Being studied"
        ],
        [
          "1HP",
          "Yes",
          "Being studied but no major DDI expected",
          "Being studied"
        ]
      ],
      "notes": "LPV/r: lopinavir/ritonavir; EFV: efavirenz; DTG: dolutegravir; 6H: six months of daily isoniazid; 3RH: three months of daily rifampicin and isoniazid; 3HP: three months of weekly isoniazid and rifapentine; 1HP: one month of daily isoniazid and rifapentine.",
      "narratives": {
        "en": "The table shows, for four TB preventive treatment regimens (6H, 3RH, 3HP, 1HP), whether they have a drug–drug interaction with the antiretrovirals LPV/r, EFV and DTG used in children and adolescents with HIV.",
        "ar": "يبيّن الجدول، لأربعة نظم للعلاج الوقائي من السل (6H، 3RH، 3HP، 1HP)، ما إذا كان لها تداخل دوائي مع مضادات الفيروسات القهقرية LPV/r وEFV وDTG المستخدمة لدى الأطفال والمراهقين المصابين بفيروس العوز المناعي البشري.",
        "zh": "该表显示四种结核病预防性治疗方案（6H、3RH、3HP、1HP）是否与儿童和青少年艾滋病毒感染者使用的抗逆转录病毒药物LPV/r、EFV和DTG存在药物相互作用。",
        "es": "La tabla muestra, para cuatro pautas de tratamiento preventivo de la tuberculosis (6H, 3RH, 3HP, 1HP), si presentan interacciones farmacológicas con los antirretrovirales LPV/r, EFV y DTG utilizados en niños y adolescentes con VIH.",
        "fr": "Le tableau indique, pour quatre schémas de traitement préventif de la tuberculose (6H, 3RH, 3HP, 1HP), s’ils présentent une interaction médicamenteuse avec les antirétroviraux LPV/r, EFV et DTG utilisés chez les enfants et adolescents vivant avec le VIH.",
        "ru": "В таблице показано, имеют ли четыре схемы профилактического лечения туберкулеза (6H, 3RH, 3HP, 1HP) лекарственные взаимодействия с антиретровирусными препаратами LPV/r, EFV и DTG, применяемыми у детей и подростков с ВИЧ."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. Prophylactic doses of drugs for children based on weight bands: daily administration",
      "pages": [
        21
      ],
      "columns": [
        {
          "titles": "Drug"
        },
        {
          "titles": "Recommended daily dose"
        },
        {
          "titles": "Formulation"
        },
        {
          "titles": "3–5.9 kg",
          "group": "Dosing"
        },
        {
          "titles": "6–9.9 kg",
          "group": "Dosing"
        },
        {
          "titles": "10–13.9 kg",
          "group": "Dosing"
        },
        {
          "titles": "14–19.9 kg",
          "group": "Dosing"
        },
        {
          "titles": "20–24.9 kg",
          "group": "Dosing"
        },
        {
          "titles": "25–29.9 kg",
          "group": "Dosing"
        },
        {
          "titles": ">30 kg",
          "group": "Dosing"
        }
      ],
      "rows": [
        [
          "Co-trimoxazole",
          "Trimethoprim 5–10 mg/kg per day",
          "Suspension\n(200 mg of sulfamethoxazole and 40 mg of trimethoprim per 5 mL)",
          "2.5 mL",
          "5 mL",
          "5 mL",
          "10 mL",
          "10 mL",
          "—",
          "—"
        ],
        [
          "",
          "",
          "Tablets (dispersible) 100/20 mg",
          "1",
          "2",
          "2",
          "4",
          "4",
          "—",
          "—"
        ],
        [
          "",
          "",
          "Tablets (scored) 400/80 mg",
          "—",
          "0.5",
          "0.5",
          "1",
          "1",
          "2",
          "2"
        ],
        [
          "",
          "",
          "Tablets (scored) 800/160 mg",
          "—",
          "—",
          "—",
          "0.5",
          "0.5",
          "1",
          "1"
        ],
        [
          "Isoniazid",
          "10–15 mg/kg per day (maximum 300 mg)",
          "100 mg (scored, dispersible)",
          "0.5",
          "1",
          "1.5",
          "2",
          "3",
          "3",
          "3"
        ],
        [
          "",
          "",
          "300 mg",
          "—",
          "—",
          "—",
          "—",
          "1",
          "1",
          "1"
        ],
        [
          "Isoniazid, co-trimoxazole and vitamin B6",
          "Isoniazid: 10–15 mg/kg per day (maximum 300 mg)",
          "300/960/25 mg",
          "—",
          "—",
          "—",
          "0.5",
          "0.5",
          "1",
          "1"
        ],
        [
          "Fluconazole",
          "6 mg/kg per day (maximum 200 mg)",
          "100 mg",
          "—",
          "0.5",
          "1",
          "1",
          "1",
          "2",
          "2"
        ]
      ],
      "notes": "— = not given (dash printed in the cell).",
      "narratives": {
        "en": "The table gives daily prophylactic doses of co-trimoxazole, isoniazid, the isoniazid/co-trimoxazole/vitamin B6 combination and fluconazole for children: for each drug and formulation, the recommended daily dose and the dose to give in each of seven weight bands from 3 kg to over 30 kg.",
        "ar": "يقدّم الجدول الجرعات الوقائية اليومية للأطفال من الكوتريموكسازول والإيزونيازيد والتوليفة إيزونيازيد/كوتريموكسازول/فيتامين B6 والفلوكونازول: لكل دواء وتركيبة، الجرعة اليومية الموصى بها والجرعة التي تُعطى في كل فئة من فئات الوزن السبع من 3 كغ إلى أكثر من 30 كغ.",
        "zh": "该表给出儿童每日预防性使用复方新诺明、异烟肼、异烟肼/复方新诺明/维生素B6复方制剂和氟康唑的剂量：针对每种药物和剂型，列出推荐日剂量以及从3公斤到30公斤以上七个体重段的给药量。",
        "es": "La tabla presenta las dosis profilácticas diarias de cotrimoxazol, isoniazida, la combinación de isoniazida/cotrimoxazol/vitamina B6 y fluconazol para niños: para cada fármaco y formulación, la dosis diaria recomendada y la dosis que debe administrarse en cada una de las siete franjas de peso, desde 3 kg hasta más de 30 kg.",
        "fr": "Le tableau donne les doses prophylactiques quotidiennes de cotrimoxazole, d’isoniazide, de l’association isoniazide/cotrimoxazole/vitamine B6 et de fluconazole chez l’enfant : pour chaque médicament et formulation, la dose quotidienne recommandée et la dose à administrer dans chacune des sept tranches de poids, de 3 kg à plus de 30 kg.",
        "ru": "В таблице приведены суточные профилактические дозы котримоксазола, изониазида, комбинации изониазид/котримоксазол/витамин B6 и флуконазола для детей: для каждого препарата и лекарственной формы указаны рекомендуемая суточная доза и доза для каждой из семи весовых групп — от 3 кг до более 30 кг."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4. Cost implications and considerations for commodities",
      "pages": [
        27
      ],
      "columns": [
        {
          "titles": "Medicines (dosage form and pack size)"
        },
        {
          "titles": "Reference price excluding transport (USD)"
        },
        {
          "titles": "Sourceᵃ"
        }
      ],
      "rows": [
        [
          "TB and co-trimoxazole preventive therapy in HIV",
          "",
          ""
        ],
        [
          "Isoniazid, 300-mg tablet, 30",
          "0.75",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Isoniazid, 100-mg tablet, 100ᵇ",
          "1.29",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Isoniazid, 300-mg tablet, 1000",
          "19.90",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Rifapentine, 150-mg tablet, 24",
          "5.00",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Rifapentine/isoniazid, 300-/300-mg tablet, 36",
          "15.00",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Isoniazid/co-trimoxazole/vitamin B6, 300-/960-/25-mg tablet, 30",
          "1.99",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Co-trimoxazole, 120-mg tablet (dispensed), 100 by 10 blister packs",
          "22.75",
          "USAID Procurement and Supply Management"
        ],
        [
          "Cryptococcal disease",
          "",
          ""
        ],
        [
          "Amphotericin B liposomal, 50 mg for injection, 1 vial",
          "16.25",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Amphotericin deoxycholate, 50 mg, 1 vial",
          "7.13",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Fluconazole, 200-mg capsule, 100",
          "6.20",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Flucytosine, 500-mg tablet, 100",
          "75.00",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "Diagnostic tests",
          "Reference price per test excluding transport (USD)",
          "Source"
        ],
        [
          "IMMY cryptococcal antigen lateral flow assay",
          "2.50",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "VISITECT® CD4 Advanced Disease rapid test",
          "3.98",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "TB LAM",
          "3.50",
          "Global Fund Pooled Procurement Mechanism"
        ],
        [
          "GeneXpert Xpert® MTB/RIF Assay, 50 cartridges",
          "528.28",
          "USAID Procurement and Supply Management"
        ],
        [
          "GeneXpert Xpert® MTB/RIF Ultra Assay, 50 cartridges",
          "499.00",
          "USAID Procurement and Supply Management"
        ]
      ],
      "notes": "Rows 1 and 9 are section headings spanning the table; row 14 repeats a header row printed for the diagnostic-tests block.\nᵃ Reference pricing from The Global Fund Pooled Procurement Mechanism and USAID Procurement and Supply Management are updated regularly.\nᵇ The price of child-friendly 100-mg tablets differs.",
      "narratives": {
        "en": "The table lists reference prices (USD, excluding transport) and procurement sources for medicines used for TB and co-trimoxazole preventive therapy and for cryptococcal disease, followed by a second block for diagnostic tests.",
        "ar": "يسرد الجدول الأسعار المرجعية (بالدولار الأمريكي، باستثناء النقل) ومصادر الشراء للأدوية المستخدمة في العلاج الوقائي من السل وبالكوتريموكسازول ولعلاج داء المستخفيات، يليها قسم ثانٍ للاختبارات التشخيصية.",
        "zh": "该表列出用于结核病和复方新诺明预防性治疗以及隐球菌病的药品参考价格（美元，不含运输费）和采购来源，随后为诊断检测的第二部分。",
        "es": "La tabla enumera los precios de referencia (USD, sin transporte) y las fuentes de adquisición de los medicamentos utilizados para el tratamiento preventivo de la tuberculosis y con cotrimoxazol y para la criptococosis, seguidos de un segundo bloque para las pruebas diagnósticas.",
        "fr": "Le tableau énumère les prix de référence (USD, hors transport) et les sources d’approvisionnement des médicaments utilisés pour le traitement préventif de la tuberculose et par le cotrimoxazole et pour la cryptococcose, suivis d’un second bloc consacré aux tests diagnostiques.",
        "ru": "В таблице приведены справочные цены (в долл. США, без учета транспортировки) и источники закупок лекарственных средств для профилактического лечения туберкулеза и котримоксазолом, а также для лечения криптококкоза; за ними следует второй блок по диагностическим тестам."
      },
      "csv": "tables/table-4.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 29,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 30,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 7
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 4
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p29); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p6); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 25,
      "note": "25 of 30 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-332907"
  }
}
